Phase 2
Completed N=159
Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension
Glaucoma · Ocular Hypertension
Source: ClinicalTrials.gov NCT06394973 ↗
Enrolled (actual)
159
Serious AEs
0.6%
Results posted
Jan 2026
Primary outcomePrimary: Mean Diurnal IOP — -5.07; -4.73; -4.6 mmHg — p=0.376
Summary
The main purpose is to compare the ocular hypotensive efficacy and safety of two concentrations of T4090 (Kinezodianone R HCl 0.2% and 0.3%) ophthalmic solution with Rhopressa® ophthalmic solution
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean Diurnal IOP |
-5.07; -4.73; -4.6 | 0.376 |
Eligibility Criteria
Main Inclusion Criteria:
- Patient (male or female) ≥18 years old
- Patient with Open Angle Glaucoma or Ocular Hypertension in both eyes
- Informed consent dated and signed.
Main Exclusion Criteria:
- Secondary Open Agle Glaucoma (ex. Pseudoexfoliation, Pigmentary glaucoma)
- Advanced stage of glaucoma
- History of ocular trauma, eye infection, or/and ocular clinically significant inflammation within the 6 previous months.
- Known or suspected hypersensitivity to one of the components of the IMPs or other product used in the clinical study
- Pregnancy (confirmed with a positive urine pregnancy test) or breast-feeding.
Data sourced from ClinicalTrials.gov (NCT06394973). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.